Company Organization and Nature of Business - Additional Information (Details) $ / shares in Units, $ in Thousands				1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 15, 2020 shares	Jun. 11, 2020 USD ($) $ / shares shares	Jun. 05, 2020	Jun. 30, 2020 shares	Sep. 30, 2021 shares	Jun. 30, 2020 shares	Sep. 30, 2021 USD ($) shares	Sep. 30, 2020 USD ($)	Jun. 17, 2020 shares
Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]
Reverse stock split			one-for-1.6870
Reverse stock split, conversion ratio			0.593
Net proceeds from initial public offering | $		$ 264,000
Underwriting discounts and commissions | $		20,100
Offering expenses | $		$ 3,400						$ 3,368
Redeemable Convertible Preferred Stock
Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]
Conversion of preferred stock (in shares)				28,610,337
Redeemable convertible preferred stock, shares outstanding					0		0		0
Common Stock
Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]
Shares issued and sold					498,502	17,968,750
Conversion of preferred stock (in shares)	28,610,337					28,610,337
Initial Public Offering
Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]
Shares issued and sold		17,968,750
Underwriters’ option to purchase additional shares		2,343,750
Public offering price per share | $ / shares		$ 16.00
Pneumococcal Conjugate Vaccine
Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]
Global target revenue | $							$ 7,000,000